Acrivon Therapeutics Inc (ACRV)

$2.39 +0.07 (3.02%)
Market Cap 73.21M
Revenue (ttm) 0.00
Net Income (ttm) -80.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 88,800
Avg Vol 771,012
Day's Range N/A - N/A
Shares Out 31.56M
Stochastic %K 45%
Beta 1.75
Analysts Strong Sell
Price Target $11.17

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 207 8979
Website: acrivon.com
Address:
480 Arsenal Way, Suite 100, Watertown, United States
AllocationApex
AllocationApex Dec. 25 at 4:18 PM
$ACRV The investment case increasingly rests on operational credibility rather than long‑range promises. Cost discipline must coexist with targeted investment. A series of confirmed wins might reduce the required risk premium. In short, this remains an execution‑driven story with meaningful but conditional upside.
0 · Reply
OilBaronOllie
OilBaronOllie Dec. 24 at 10:49 AM
$ACRV Investor conviction will hinge on whether timelines compress uncertainty rather than extend speculation. Clear inflection points are required to justify renewed interest.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 4:04 PM
$ACRV RSI: 50.95, MACD: 0.0278 Vol: 0.13, MA20: 2.39, MA50: 2.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
3 · Reply
Jstidd
Jstidd Dec. 22 at 5:15 PM
$ACRV cruising!
0 · Reply
elmono
elmono Dec. 19 at 6:49 PM
$ACRV price action on this turd starting to annoy me..WTF. Pivotal data read out in wks 🤷‍♂️
0 · Reply
Monty3030
Monty3030 Dec. 19 at 4:09 PM
$ACRV I had mention this was coming back down to 2.15 before going back up but people thought I was crazy.
2 · Reply
Doudiane
Doudiane Dec. 18 at 6:25 PM
$ACRV mmmm why this low?
2 · Reply
KingShark7
KingShark7 Dec. 18 at 4:53 PM
$ACRV loading
0 · Reply
mankind1
mankind1 Dec. 17 at 11:28 PM
$ACRV taking a look 👀
0 · Reply
Kingcrab33333
Kingcrab33333 Dec. 17 at 11:13 PM
$ACRV (load)
0 · Reply
Latest News on ACRV
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Dec 17, 2025, 9:34 AM EST - 8 days ago

UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 13, 2025, 4:10 PM EST - 6 weeks ago

Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Oct 22, 2025, 4:15 PM EDT - 2 months ago

Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2025, 4:30 PM EDT - 3 months ago

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 13, 2025, 4:15 PM EDT - 4 months ago

Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 4:10 PM EDT - 8 months ago

Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Apr 25, 2025, 8:00 AM EDT - 8 months ago

Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Apr 7, 2025, 4:05 PM EDT - 9 months ago

Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 5:44 PM EDT - 9 months ago

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Mar 19, 2025, 8:00 AM EDT - 10 months ago

Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Dec 12, 2024, 3:25 PM EST - 1 year ago

Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Oct 11, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Sep 18, 2024, 10:11 AM EDT - 1 year ago

Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Sep 14, 2024, 3:10 AM EDT - 1 year ago

Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

Jun 13, 2024, 2:00 PM EDT - 1 year ago

Acrivon Therapeutics: Can You Win In Clinical Trials With Selection Bias?

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics to Present at the Jefferies Global Healthcare Conference

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 14, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Apr 24, 2024, 7:16 PM EDT - 1 year ago

Acrivon Therapeutics' shares climb 14% on plans to present cancer-test data

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Apr 16, 2024, 8:01 PM EDT - 1 year ago

Acrivon Therapeutics to Host Corporate R&D Event Highlighting AP3 and Pipeline Progress, Including Ongoing Prospective Validation of ACR-368 OncoSignature with Initial Phase 2 Data for ACR-368, and Preclinical Progress for ACR-2316

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Acrivon Therapeutics Announces $130 Million Private Placement Financing

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Acrivon Therapeutics Announces $130 Million Private Placement Financing

What To Buy After You Sell The Russell 2000

Apr 3, 2024, 3:07 AM EDT - 1 year ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Mar 5, 2024, 4:30 PM EST - 1 year ago

Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 1 year ago

Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2024, 4:00 PM EST - 2 years ago

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Nov 21, 2023, 8:00 AM EST - 2 years ago

Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 9, 2023, 8:01 AM EST - 2 years ago

Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Sep 19, 2023, 4:32 PM EDT - 2 years ago

Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on M

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Sep 5, 2023, 4:05 PM EDT - 2 years ago

Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon's AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Participate in Two Investor Conferences in September

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 11, 2023, 7:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Jun 22, 2023, 4:00 PM EDT - 2 years ago

Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Jun 2, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Jefferies Healthcare Conference

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 9, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Apr 18, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 26, 2023, 9:53 AM EDT - 2 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 6, 2023, 8:00 AM EST - 3 years ago

Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Nov 14, 2022, 10:16 PM EST - 3 years ago

Acrivon Therapeutics Announces Pricing of Initial Public Offering

Acrivon Therapeutics sets IPO price range

Nov 3, 2022, 7:52 AM EDT - 3 years ago

Acrivon Therapeutics sets IPO price range

Acrivon Therapeutics Begins U.S. IPO Rollout

Oct 19, 2022, 11:50 AM EDT - 3 years ago

Acrivon Therapeutics Begins U.S. IPO Rollout

AllocationApex
AllocationApex Dec. 25 at 4:18 PM
$ACRV The investment case increasingly rests on operational credibility rather than long‑range promises. Cost discipline must coexist with targeted investment. A series of confirmed wins might reduce the required risk premium. In short, this remains an execution‑driven story with meaningful but conditional upside.
0 · Reply
OilBaronOllie
OilBaronOllie Dec. 24 at 10:49 AM
$ACRV Investor conviction will hinge on whether timelines compress uncertainty rather than extend speculation. Clear inflection points are required to justify renewed interest.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 4:04 PM
$ACRV RSI: 50.95, MACD: 0.0278 Vol: 0.13, MA20: 2.39, MA50: 2.20 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
3 · Reply
Jstidd
Jstidd Dec. 22 at 5:15 PM
$ACRV cruising!
0 · Reply
elmono
elmono Dec. 19 at 6:49 PM
$ACRV price action on this turd starting to annoy me..WTF. Pivotal data read out in wks 🤷‍♂️
0 · Reply
Monty3030
Monty3030 Dec. 19 at 4:09 PM
$ACRV I had mention this was coming back down to 2.15 before going back up but people thought I was crazy.
2 · Reply
Doudiane
Doudiane Dec. 18 at 6:25 PM
$ACRV mmmm why this low?
2 · Reply
KingShark7
KingShark7 Dec. 18 at 4:53 PM
$ACRV loading
0 · Reply
mankind1
mankind1 Dec. 17 at 11:28 PM
$ACRV taking a look 👀
0 · Reply
Kingcrab33333
Kingcrab33333 Dec. 17 at 11:13 PM
$ACRV (load)
0 · Reply
Kingcrab33333
Kingcrab33333 Dec. 17 at 11:07 PM
$ACRV
0 · Reply
Dani_G_German
Dani_G_German Dec. 17 at 8:40 PM
$ACRV added here
0 · Reply
JohnTrack
JohnTrack Dec. 17 at 4:38 PM
$ACRV counting the minutes until the announcement... https://www.rapidticker.com/news/acrv-update-acrivon-therapeutics-to-announce-87ca95
0 · Reply
TwongStocks
TwongStocks Dec. 17 at 12:31 PM
$ACRV Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates https://ir.acrivon.com/news-releases/news-release-details/acrivon-therapeutics-announce-clinical-update-its-ongoing-phase in January 2026
1 · Reply
Jstidd
Jstidd Dec. 16 at 6:09 PM
$ACRV news after hours? 🤞🏼
1 · Reply
Doudiane
Doudiane Dec. 16 at 5:36 PM
$ACRV last chance to buy this…
0 · Reply
Kingcrab33333
Kingcrab33333 Dec. 16 at 6:15 AM
$ACRV
0 · Reply
Monty3030
Monty3030 Dec. 15 at 3:11 PM
$ACRV Will probably come back down around 2.15 before we get news
1 · Reply
Doudiane
Doudiane Dec. 14 at 7:13 PM
$ACRV i fing this i. X , i dont know if it real
1 · Reply
Doudiane
Doudiane Dec. 13 at 11:10 PM
$ACRV 14 december, No H2 results yet… hopefully soon
0 · Reply
Monty3030
Monty3030 Dec. 13 at 12:22 PM
$ACRV Looking forward to seeing where this goes in 2026!
0 · Reply
Djdanny
Djdanny Dec. 12 at 5:19 PM
$ACRV $LSTA My next winner
0 · Reply